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OBJECTIVES This study evaluated myocardial function in relation to high-energy phosphate (HEP)
metabolism in asymptomatic patients with uncomplicated type 2 diabetes mellitus using
magnetic resonance (MR) techniques.
BACKGROUND Myocardial dysfunction may occur in patients with type 2 diabetes mellitus in the absence of
coronary artery disease or left ventricular (LV) hypertrophy. The mechanisms underlying this
diabetic cardiomyopathy are largely unknown, but may involve altered myocardial energy
metabolism.
METHODS We assessed myocardial systolic and diastolic function and HEP metabolism in 12
asymptomatic normotensive male patients with recently diagnosed, well-controlled type 2
diabetes and 12 controls, using MR imaging and phosphorus-31-nuclear MR spectroscopy
(31P-MRS) on a 1.5 T clinical scanner; 31P-MR spectra were quantified, and myocardial
HEP metabolism was expressed as phosphocreatine to adenosine-triphosphate (PCr/ATP)
ratio.
RESULTS No differences were found in LV mass and systolic function between patients and controls.
However, early (E) acceleration peak, deceleration peak, peak filling rate, and transmitral
early-to-late diastolic peak flow (E/A) ratio, all indexes of diastolic function, were signifi-
cantly decreased in patients compared with controls (p  0.02). In addition, myocardial
PCr/ATP in patients was significantly lower than in controls (1.47 vs. 1.88, p  0.01).
Inverse associations were found between myocardial PCr/ATP and E acceleration peak, E
deceleration peak, and E peak filling rate (all, p  0.05).
CONCLUSIONS These results indicate that altered myocardial energy metabolism may contribute to LV
diastolic functional changes in patients with recently diagnosed, well-controlled and uncom-
plicated type 2 diabetes. (J Am Coll Cardiol 2003;42:328–35) © 2003 by the American
College of Cardiology Foundation
Type 2 diabetes mellitus is associated with an increased risk
of cardiovascular disease (CVD) (1). In particular, diabetic
patients have a higher incidence of congestive heart failure
as compared with age-matched nondiabetic subjects (2).
Higher left ventricular (LV) mass and LV dysfunction was
observed in newly diagnosed type 2 diabetic patients with-
out clinically manifest heart disease (3,4). Myocardial func-
tional abnormalities in diabetes have been related to hyper-
glycemia by some authors (5,6), but were found to be
independent of glycemic control by others (7). In the
absence of coronary artery disease (CAD) and hypertension,
myocardial structural and functional changes in patients
with diabetes have been ascribed to diabetic cardiomyopathy
(DCM) (8,9).
Several causative mechanisms for DCM have been pos-
tulated, including microangiopathy, autonomic nervous dys-
function, defective cellular calcium transport, as well as
structural changes in myocardial contractile proteins and
accumulation of collagen, leading to increased stiffening of
the ventricular wall. However, the exact pathogenesis of this
condition has as yet not been elucidated (8). Recent evi-
dence suggests that alterations in myocardial energy metab-
olism, resulting from altered substrate supply and utilization
by cardiac myocytes, may be the primary injury in the
pathogenesis of DCM (9–11). In the diabetic heart, myo-
cardial energy status may be reduced as a result of inappro-
priate use of elevated free fatty acids (FFA) as a metabolic
substrate, which may by cycled through intramyocardial
lipolysis and re-esterified, leading to accumulation of po-
tentially toxic intermediates and suppression of glucose
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metabolism (9–12). The altered myocardial energy metab-
olism may adversely affect myocardial function.
Using magnetic resonance imaging (MRI) and phosphorus-
31 nuclear magnetic resonance spectroscopy (31P-MRS),
the simultaneous existence of diastolic dysfunction and
altered myocardial high-energy phosphate (HEP) metabo-
lism was previously demonstrated in hypertensive patients
with increased LV mass (13). The purpose of the present
study was to study LV systolic and diastolic function in
relation to myocardial energy metabolism, using these mag-
netic resonance (MR) techniques, in normotensive patients
with well-controlled type 2 diabetes mellitus of short
duration who had no clinical evidence of CAD.
METHODS
Subjects. Twelve male patients with uncomplicated type 2
diabetes and 12 age- and gender-matched healthy controls
were studied. Patients (aged 50 to 65 years) were selected
from general practices after approval of their physicians.
Selection criteria were type 2 diabetes of short duration (5
years, diagnosed by WHO criteria) (14); no signs or
symptoms or history of CVD; and a normal electrocardio-
gram (ECG), body mass index (BMI)  28 kg/m2, seated
office blood pressure (BP)  150/90 mm Hg, good meta-
bolic control (glycated hemoglobin [HbA1c]  7.8%), no
use of drugs other than sulfonylureas and/or metformin; and
no diabetic complications including albuminuria, retinopa-
thy, and neuropathy. Healthy controls who had no history
or clinical evidence of CVD were included through adver-
tisements in local newspapers. During a screening visit, a
medical history (including a short questionnaire regarding
physical fitness in which the participants estimated the time
spent performing moderate exercise such as walking, biking,
and swimming), physical examination (including standard-
ized measurements of the vibration sense and Ewing’s
cardiovascular tests [15]), an ECG, and screening laboratory
tests were obtained from all participants; HbA1c was
determined by high performance liquid chromatography
after hemolysis (reference range, 4.3 to 6.3% in nondiabetic
subjects) (Bio Rad, Richmond, California). Microalbumin-
uria was determined in a 24-h urine collection and measured
by immunonephelometry (Array Protein System, Beckman,
Fullerton, California) (normoalbuminuria was defined as
albumin/creatinine ratio [ACR]  2.5 mg/mmol). Mean
ACR in patients was 0.5  0.5 mg/mmol and 0.4  0.3
mg/mmol in controls (p  0.454). In patients only, fundus
photography was performed, unless a recent (6 months)
written report from the patient’s ophthalmologist was avail-
able. Laboratory determinations were performed according
to standard procedures. Subjects with metallic implants
were excluded. Patients were asked to stop their medication
one week before the MR studies. The protocol was ap-
proved by the local ethics committee, and all subjects gave
informed consent.
MRI. All MR studies were performed using a 1.5-T
whole-body MR scanner (Gyroscan ACS/NT15; Philips,
Best, the Netherlands) equipped with multinuclei hardware
for 31P-MRS; MRI and MR spectroscopy were performed
at a single occasion, at rest and in the supine position. The
entire heart was imaged in the short-axis orientation using
breath-hold multishot echo-planar imaging as described
earlier (16); MRI velocity mapping with retrospective
ECG-gating was performed to measure flow (expressed as
ml/s) across the mitral valve and through the ascending
aorta (13,17). During the entire MR examination, BP and
heart rate (HR) were recorded every 2 min with a semiau-
tomated device (Dinamap, Critikon, Tampa, Florida). Im-
age analyses were performed by two blinded trained observ-
ers; LV functional parameters were calculated as described
previously (18). The surface areas of the endocardial tracings
in end diastole and end systole were summed up and
multiplied by section thickness and section factor to produce
the end-diastolic chamber volume (EDV) and end-systolic
chamber volume (ESV). Stroke volume (SV) was the
difference between EDV and ESV. Cardiac output was SV
multiplied by the average HR, and cardiac index was cardiac
output divided by body surface area. Ejection fraction was
SV divided by the EDV. The difference between the
summed end-systolic epicardial and endocardial borders
multiplied by section thickness and section factor served as
an estimate of wall volume (18). Wall volume was multi-
plied by the specific density of cardiac muscle (1.05 g/cm3)
to obtain wall mass. Acceleration and deceleration peak
values were calculated as the maximal change in ml/s
(expressed as ml/s2) obtained from the velocity encoded
MRI acquisitions (13).
31P-MRS. A 100-mm-diameter surface coil was used to
acquire 31P-MR spectra of the LV anterior wall. The coil
was placed over the precordium and secured with a Velcro
strap to minimize respiratory artifacts. Volumes of interest
were selected by image-guided spectroscopy using image-
selected in vivo spectroscopy (ISIS) based on transverse and
Abbreviations and Acronyms
ACR  albumin/creatinine ratio
ATP  adenosine-triphosphate
CAD  coronary artery disease
CK  creatine kinase
CVD  cardiovascular disease
DCM  diabetic cardiomyopathy
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EDV  end-diastolic volume
ESV  end-systolic volume
FFA  free fatty acids
HEP  high-energy phosphate
LV  left ventricle/ventricular
MR  magnetic resonance
MRI  magnetic resonance imaging
PCr  phosphocreatine
SV  stroke volume
31P-MRS  phosphorus-31 magnetic resonance
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sagittal spin-echo MR scout images. The entered volume
size was typically 6 (caudo-cranial)  7  7 cm3. Because
the predicted maximal effective depth of the surface coil was
approximately 9 cm below the coil center, the exact distance
in the posterior direction was determined by coil sensitivity.
In practice, 31P-MR spectra are mainly obtained from the
LV anterior wall. Acquisitions were based on 192 averaged
free induction decays, and total acquisition time was 10 min;
31P-MR spectra were transferred to a remote SUN-SPARC
work station for analysis according to previously described
methods (19–22). Briefly, 31P-MR spectra were quantified
automatically in the time domain and were corrected for
partial saturation effects and for the adenosine-triphosphate
(ATP) contribution from blood in the cardiac chambers as
described earlier (21,23). Myocardial HEP metabolism was
quantified as phosphocreatine to ATP (PCr/ATP) ratio.
The ratio of ATP to 2,3-diphosphoglycerate (2,3-DPG)
was 0.36 and was used in the present study to calculate the
contribution of blood ATP to the observed ATP signal in
cardiac 31P-MR spectra. In addition, depending on the
repetition time (TR), PCr/ATP ratios also had to be
corrected for partial saturation effects; T1 values of a recent
study were used, obtained from inversion recovery experi-
ments on the human left ventricle, and were 4.43 s for PCr,
2.61 s for -ATP, 2.51 s for -ATP, and 2.67 s for -ATP.
Based on these data and a TR of 3.6 s, a saturation
correction factor of 1.35 was obtained and applied to all
“blood corrected” myocardial PCr/ATP ratios acquired in
the present study (19,22,23). Other tissues, such as liver and
diaphragm/skeletal muscle were carefully excluded from the
volume of interest, and, therefore, did not contribute to the
final spectrum. Other technical details were similar as
described earlier (19,20).
Statistical analysis. Data are mean  SD or median
(range) if not normally distributed. The normal distribution
was tested using the Shapiro-Wilk test. Differences between
patients and controls were assessed by unpaired two-tailed
Student t test. Because only minor differences in clinically
relevant variables were found between the two groups, data
of patients and controls were pooled to assess correlations
between variables by Pearson’s correlation test or by univar-
iate regression analyses. A p value  0.05 was considered
statistically significant.
RESULTS
Subject characteristics. Table 1 lists the characteristics of
patients and controls. Patients and controls differed with
respect to HbA1c, fasting plasma glucose, insulin,
C-peptide, and high-density lipoprotein cholesterol con-
centrations; otherwise they had similar age, BMI, and BP.
Three of 12 patients were treated by diet only, three used
sulfonylureas, two metformin, and four were treated by
sulfonylureas and metformin (data not shown). Median
self-reported estimated time spent performing moderate
exercise (walking, biking, or swimming) was 60 min (range
30 to 180) per week, and this was comparable in patients
and controls (data not shown). No deterioration of glycemic
control was observed after one week of discontinuation of
antidiabetic medication (mean fasting glucose levels, 8.1 
1.7 [before] vs. 8.2  1.6 [after]; p  0.722).
Myocardial function and metabolism. Left ventricular
mass was similar in both groups, as well as indexes of
Table 1. Clinical Characteristics of Diabetic and
Control Subjects
Patients
(n  12)
Controls
(n  12)
Age (yrs) 56  6 54  7
Duration of disease (months) 14 (6–60) NA
BMI (kg/m2) 25.4  1.6 24.2  1.6
Systolic BP (mm Hg) 135  8 134  9
Diastolic BP (mm Hg) 83  6 79  7
Heart rate (beats/min) 69  10 66  12
Rate pressure product
(mm Hg  beats/min  102)
93  16 83  19
HbA1c (%) 6.1  1.1† 5.0  0.6
Fasting plasma glucose (mmol/l) 8.2  1.6† 5.5  0.4
Fasting plasma insulin (MU/I) 17.8  9.9* 10.0  3.2
C-peptide (nmol/l) 1.1  0.4† 0.7  0.2
Total cholesterol (mmol/l) 5.4  0.8 5.3  0.9
HDL cholesterol (mmol/l) 1.0  0.3† 1.5  0.3
Triglycerides (mmol/l) 1.8  0.9 1.5  1.2
LDL cholesterol (mmol/l) 3.9  0.7 3.5  0.9
Values are mean  SD or median (range). *p  0.05; †p  0.02.
BMI body mass index; BP blood pressure; HDL high-density lipoprotein;
LDL  low-density lipoprotein; NA  not applicable.
Table 2. Left Ventricular Dimensions and Systolic Function
Parameters Patients Controls r to PCr/ATP
LV mass (g) 120  25 125  27 0.030
LV mass index (g/m2) 59  11 64  13 0.128
End-diastolic volume (ml) 143  19 149  18 0.125
End-systolic volume (ml) 58  14 58  6 0.040
Stroke volume (ml) 85  15 92  15 0.121
Stroke index (ml/m2) 42  8 47  7 0.239
Ejection fraction (%) 59  8 61  4 0.024
Cardiac output (l/min) 5.8  1.2 6.0  1.1 0.254
Cardiac index (l/min/m2) 2.8  0.6 3.0  0.5 0.174
End-systolic wall stress (kN/m2) 46  8 43  7 0.164
Values are mean  SD. Statistical analysis showed no differences between patients and controls, no significant correlations.
ATP  adenosine-triphosphate; LV  left ventricular; PCR  phosphocreatine; r  Pearson’s correlation coefficient.
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systolic function (Table 2). However, parameters of diastolic
function, including early to late diastolic (E/A) peak flow
ratio (p  0.019), early peak filling rate (p  0.016), early
acceleration peak (p  0.010), and early deceleration peak
(p  0.05) were lower in patients (Table 3). On average, in
diabetic patients E/A peak flow ratio was 22%, early peak
filling rate 24%, early acceleration peak 23%, and early
deceleration peak 24% lower than in controls.
In patients, mean PCr/ATP was significantly lower than
in controls (Fig. 1, A) (1.47  0.28 vs. 1.88  0.34, p 
0.01). Figure 1, B, shows representative 31P-MR spectra of
a patient (upper panel) and nondiabetic subject (lower
panel). When data from patients and controls were pooled,
significant correlations were found between myocardial
PCr/ATP and LV diastolic functional parameters (Table 3):
early peak filling rate (r  0.504, p  0.014), early
acceleration peak (r  0.497, p  0.016), and early
deceleration peak (r  0.420, p  0.046). Figure 2 shows
the association between myocardial PCr/ATP and indexes
of diastolic function in patients and controls. No associa-
tions were found between myocardial HEP metabolism and
indexes of systolic function or LV mass (Table 2).
To evaluate the mathematical determinants of the ob-
served decrease in myocardial PCr/ATP in patients, PCr
and ATP values were calculated separately in arbitrary units.
In patients, PCr was 5.8  1.9, as compared with 8.1  2.3
in healthy subjects (p  0.02); ATP in patients was 4.0 
1.1, as compared with 4.4  1.3 in healthy subjects (p 
Figure 1. (A) Mean  SD myocardial phosphocreatine to adenosine-triphosphate (PCr/ATP) ratios in type 2 diabetic patients (solid bar) and controls
(open bar). *p  0.01. (B) Representative phosphorus-31 magnetic resonance spectroscopy (31P-MRS) obtained at rest from the anterior left ventricular
wall of a patient (upper panel) and healthy subject (lower panel). The peaks of PCr, ATP, and inorganic phosphate (Pi) plus 2,3-diphospho-glycerate
(2,3-DPG) are identified in the upper panel. Myocardial PCr/ATP ratios, as presented below the 31P-MRS, were corrected for partial saturation effects
and blood-ATP contamination, and line broadening of 15 Hz was applied.
Table 3. Left Ventricular Diastolic Function
Parameters Patients Controls r to PCr/ATP
E/A peak flow 1.07  0.3† 1.40  0.4 0.199
E peak filling rate (ml/s) 394  79† 492  102 0.504†
E peak filling rate/EDV (s1) 2.7  0.5 3.2  0.6 0.464*
E acceleration peak (ml/s2)  103 6.4  1.6† 8.2  1.7 0.497†
E deceleration peak (ml/s2)  103 3.1  0.9* 4.0  1.3 0.420*
A peak filling rate (ml/s) 382  73 363  76 0.248
A peak filling rate/EDV (s1) 2.7  0.5 2.4  0.5 0.193
A acceleration peak (ml/s2)  103 7.2  1.6 7.4  2.0 0.026
A deceleration peak (ml/s2)  103 7.3  2.1 7.1  3.4 0.045
Values are mean SD. Statistical significance is indicated for comparisons between groups or correlations: *p 0.05; †p 0.02.
A  atrial; E  early; EDV  end-diastolic volume. Other abbreviations as in Table 2.
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0.05). Therefore, the observed decrease in myocardial PCr/
ATP in patients may be explained by a decrease in the
derived signal for PCr.
When data from patients and controls were pooled, E/A
peak flow was negatively associated with age (r  0.605,
p  0.002), BMI (r  0.468, p  0.021), and fasting
plasma glucose (r  0.396, p  0.05) and positively with
high-density lipoprotein cholesterol (r  0.419, p 
0.041). Myocardial PCr/ATP was inversely associated with
HbA1c (r  0.631, p  0.001), and there was a trend for
an association with fasting plasma glucose (r0.399, p
0.06) and fasting plasma insulin (r  0.406, p  0.054;
Table 4). A significant inverse association was found be-
tween the level of cardiac workload (rate pressure product)
and myocardial PCr/ATP (r  0.413, p  0.049; not
shown in Table 4).
DISCUSSION
The present data support earlier findings (4,7) indicating
that patients with type 2 diabetes, free of clinical CAD, have
(subclinical) LV diastolic dysfunction with normal systolic
function. This study indicates that myocardial PCr/ATP is
reduced and associated with altered diastolic function in
patients with type 2 diabetes, despite good metabolic
control and normal BP.
The existence of myocardial dysfunction, both systolic (3)
and diastolic (4,6,7), in patients with type 2 diabetes in the
absence of CAD has been ascribed to DCM. The patho-
genesis of DCM, however, remains unclear, although sev-
eral mechanisms, including microvascular and metabolic
alterations of the diabetic myocardium have been proposed
(8). Hypertension is present in up to 70% of type 2 diabetic
patients, and poor metabolic control (3,8) may play an
important role in the development of myocardial dysfunc-
tion. However, LV diastolic dysfunction was also described
in normotensive patients with well-controlled type 2 diabe-
tes in the absence of CAD (24). In that study, however, no
control group was included, and the echocardiographic
measurements were compared with historical reference val-
ues. Using MRI, we found altered LV diastolic function in
asymptomatic, non-obese and normotensive patients with
well-controlled, recently diagnosed type 2 diabetes, as com-
pared with controls who were matched for age, gender,
BMI, and BP. In our study, patients had no LV hypertro-
phy in contrast with previous findings in type 2 diabetic
subjects (3,5). Using MRI we found lower LV mass values
than those measured by echocardiography, which seems to
overestimate LV geometry (25).
The clinical relevance of diastolic dysfunction in asymp-
tomatic patients in terms of prognosis and treatment still
needs to be determined. Recently, Poirier et al. (26) found
that asymptomatic type 2 diabetic patients with impaired
LV diastolic function had lower maximal treadmill perfor-
mance than patients with normal diastolic function. Because
interventions such as aerobic exercise and angiotensin-
Figure 2. The association between myocardial phosphocreatine/adenosine-
triphosphate (PCr/ATP) and E peak filling rate (A) and E acceleration
peak (B), representing indexes of diastolic function, in type 2 diabetic
patients (solid dots) and healthy controls (open dots). See also Table 3 and
text.
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converting enzyme inhibition may improve diastolic func-
tion (27,28), early detection may have therapeutic implica-
tions.
We found significantly lower resting myocardial PCr/
ATP in type 2 diabetic patients as compared with controls.
Previously, we reported similar findings in nondiabetic
patients with hypertension and LV hypertrophy (13). We
then suggested that reduced PCr/ATP may be explained by
a decrease in creatine kinase (CK) activity and lower total
creatine content, accompanied by a switch in myocardial
substrate utilization from FFA to glucose, which occurs
during exercise-stress, in the hypertrophied myocardium
and in ischemic heart disease (13,29). However, myocardial
substrate availability and utilization may be also altered due
to type 2 diabetes, even in the absence of LV hypertrophy
(9,10). In perfused hearts from type 2 diabetic db/db mice,
the rate of glycolysis and glucose oxidation was impaired
due to reduced content of insulin-sensitive glucose
(GLUT4) transporters, whereas palmitate oxidation was
increased (30). In obese Zucker Diabetic Fatty (ZDF fa/fa)
rats, triglyceride accumulation in the heart was observed
(11). These changes were associated with increases of
ceramide content, a mediator of apoptosis, and inducible
nitric oxide (NO) synthase expression. Clinically, these rats
exhibited LV diastolic dysfunction (11); NO was found to
inhibit CK and impair contractile reserve in rat hearts (31).
Thus, lipotoxicity may be an important mechanism under-
lying myocardial dysfunction in obesity and diabetes (11).
In humans, the impact of type 2 diabetes on myocardial
metabolism is difficult to study, not only because it requires
the use of expensive and experimental methods such as
positron emission, single-photon emission tomography and
MR spectrometry (13,32–36), but also mainly because of
the heterogeneity of this patient group with a high preva-
lence of comorbid conditions such as CAD, hypertension,
and the use of multiple drugs, including insulin. As a
consequence, conflicting data on myocardial metabolism in
type 2 diabetic patients have been reported, including
decreased (32) and normal (33) myocardial glucose utiliza-
tion, impaired (34,35) and normal (36) FFA metabolism,
and increased triglyceride synthesis (34). Although 31P-
MRS measurements do not link the CK system to specific
metabolic pathways in the heart, in theory, three factors may
explain the lower PCr/ATP observed in our patients as
compared with controls. First, the difference in prevailing
metabolic substrates as well as insulin levels may have
adversely affected myocardial PCr/ATP. Secondly, triglyc-
eride accumulation in cardiomyocytes may not only impair
substrate oxidation but also induce nonoxidative metabolic
pathways with subsequent formation of toxic intermediates,
thus compromising myocardial energy metabolism. In ad-
dition to the mechanisms described in rats (11), another
possible mechanisms underlying “lipotoxicity” linking met-
abolic substrate use to the CK system may be the proposed
inhibition of mitochondrial adenine nucleotide translocators
by increased intracellular long-chain acyl-CoA esters, re-
sulting in a decreased cytosolic ATP/ADP ratio (37).
Finally, subclinical ischemia may decrease PCr/ATP, result-
ing in reduction of both glucose and FFA oxidation, with
glycolysis becoming the dominant source of energy produc-
tion. This uncoupling of glycolysis from glucose oxidation
causes anaerobic hydrolysis of ATP and excessive produc-
tion of cytosolic protons, resulting in intracellular acidosis
(9). Subsequently, these protons need to be exchanged for
other cations, leading to intracellular calcium overload.
Moreover, ATP is needed to re-establish cation homeosta-
sis, which contributes to a decrease in cardiac energy
efficiency during ischemia (38). All these mechanisms,
however, need to be confirmed in humans in vivo.
We found an association between myocardial diastolic
dysfunction and abnormal HEP metabolism in subjects
with type 2 diabetes and normal LV mass. Although altered
myocardial metabolism may contribute to the observed
functional changes, no causative relation was established in
this study. From previous studies in nondiabetic humans
with LV hypertrophy, it was suggested that the lower PCr
content and the switch in substrate preference from fatty
acids to glucose may lead to lower levels of ATP at the
sarcomeres, which is not compensated for by increased
mitochondrial ATP production (13). Lower cytosolic ATP
concentration is associated with impaired calcium seques-
tration by the sarcoplasmatic reticulum and impaired relax-
ation of cardiomyocytes and may be responsible for the
diastolic dysfunction observed. Similarly, the lower myocar-
dial PCr/ATP in our diabetic patients could mathematically
be explained by a decrease in the derived signal for PCr,
while ATP levels were not different from controls. Al-
though our patients had no LV hypertrophy, the metabolic
changes in diabetic patients leading to altered substrate
availability for myocardial energy metabolism may converge
on similar cellular mechanisms resulting in diastolic dys-
function. Indeed, in lean patients with type 2 diabetes, a
correlation between reduced FFA uptake and LV wall
motion abnormalities was observed (35). Also, several re-
ports described the relation between systemic hyperglycemia
and LV diastolic dysfunction (6,7). In our study, diastolic
Table 4. Univariate Coefficients for Correlation Between
Diastolic Function, Myocardial Metabolism, and Metabolic and
Cardiovascular Risk Factors in Patients With Type 2 Diabetes
and Controls
E/A Peak Flow
PCr/ATP
Ratio
Age 0.605† 0.063
BMI 0.468* 0.158
Systolic BP 0.173 0.048
HbA1c 0.001 0.631†
Fasting plasma glucose 0.396* 0.399
Fasting plasma insulin 0.182 0.406
HDL cholesterol 0.419* 0.398
*p  0.05; †p  0.02.
A atrial; ATP adenosine-triphosphate; BMI body mass index; BP blood
pressure; E  early; HDL  high-density lipoprotein; PCR  phosphocreatine.
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dysfunction was associated with BMI and fasting plasma
glucose and low high-density lipoprotein cholesterol levels,
that is, components of the insulin resistance syndrome.
Clearly, the cellular mechanisms underlying the observed
association between altered myocardial HEP metabolism
and diastolic functional changes in type 2 diabetic subjects
need further research.
Study limitations. The number of subjects evaluated in the
present study was limited, mainly due to the demanding
combined MR imaging and 31P-MR spectroscopy exami-
nations. However, the sample size was sufficient to show
statistically significant differences between healthy controls
and patients, and significant correlations between myocar-
dial function and metabolism.
Because we did not perform angiography, the possibility
of the presence of CAD in our patients cannot be entirely
excluded. However, none of the subjects had evidence of
CAD based on clinical history, examination, ECG, or wall
motion analysis by MRI (data not shown). Thus, although
subclinical atherosclerosis may have been present, CAD is
unlikely to be an important confounding variable in explain-
ing the observed alterations in LV diastolic function and
metabolism.
Although long-term effects of sulfonylureas on cardiac
function and metabolism cannot be ruled out entirely, it is
unlikely that these agents have influenced the results. First,
patients stopped taking these agents one week before the
MR studies, and, second, no differences in functional and
metabolic parameters were found between subjects taking
drugs and those treated by diet only (data not shown).
Only baseline assessment of circulating metabolic sub-
strates was performed. Therefore, our future studies will
assess the impact of prevailing concentrations of metabolic
substrates on myocardial energy metabolism and function by
performing cardiac MR examinations before and after
manipulation of systemic glucose, insulin and/or fatty acids
levels.
Finally, diastolic functional parameters are sensitive for
loading conditions (i.e., preload and afterload), which were
not evaluated in detail, and should be incorporated in future
research.
Conclusions. Impaired LV diastolic function in associa-
tion with reduced myocardial HEP metabolism was ob-
served in patients with well-controlled and uncomplicated
type 2 diabetes. These results may contribute to the under-
standing of the pathophysiology and natural course of
diabetic cardiomyopathy. Future studies are needed to
further explore the determinants of myocardial function and
metabolism and to establish the implications of these
findings in this high-risk population.
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